Volume 9, Number 7—July 2003
Dispatch
Serologic Evidence of West Nile Virus Infection in Horses, Yucatan State, Mexico
Table 2
Horse | Sampling date | Study site | Age (y) | Sex | Clinical symptoms | Outcome | HI assay titer | % inhibition by blocking ELISAb |
|
---|---|---|---|---|---|---|---|---|---|
3.1112Gc | 6B6C-1d | ||||||||
H-60 |
July 2, 2002 |
Merida |
8 |
Male |
Gastrointestinal (recurrent colic) |
Survived |
10 |
0 |
59 |
H-117 |
July 5, 2002 |
Tizimin |
7 |
Male |
None |
Survived |
10 |
84 |
93 |
H-126 |
July 5, 2002 |
Tizimin |
2 |
Male |
None |
Survived |
40 |
87 |
93 |
H-134 |
July 5, 2002 |
Tizimin |
3 |
Female |
None |
Survived |
10 |
11 |
0 |
H-141 |
July 5, 2002 |
Tizimin |
10 |
Male |
None |
Survived |
80 |
5 |
47 |
H-252 | Oct. 15, 2002 | Caucel | 3 | Male | Neurologic and muscular symptoms | Euthanized | 20 | 64 | 25 |
aHI, hemagglutination-inhibition; ELISA, enzyme-linked immunosorbent assay.
bInhibition values >30% are considered significant.
cMAb 3.1112G is WNV-specific.
dMAb 6B6C-1 is flavivirus group–reactive.
Page created: December 22, 2010
Page updated: December 22, 2010
Page reviewed: December 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.